Just – Evotec Biologics, the biologics segment of Evotec SE today announced the launch of its proprietary J.CHO™ High Expression System (“J.CHO”) for antibody expression. As part of Just – Evotec Biologics’ highly-intensified continuous bioprocessing platform, J.CHO™ optimises clinical and commercial biotherapeutic production processes by providing higher productivity and high quality of complex antibody formats, including candidate antibodies, Fc-fusions, and bispecific antibodies.
↧